A1M Pharma hereby announces that the company’s patent application No. 8,568,999 concerning the diagnosis and treatment of preeclampsia has been approved in the United States. The patent, which is valid for 20 years, is entitled ”Diagnosis and Treatment of Preeclampsia”.
CEO Tomas Eriksson comments:
– The granting of the approved patent regarding the diagnosis and treatment of preeclampsia in the U.S. gives us protection in the world’s largest pharmaceutical market and provides further breadth to our existing patent protection.
For further information please contact Thomas Eriksson, CEO of A1M Pharma AB, tel 046-286 50 30.